TECOGEN INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TECOGEN INC. on July 7, 2017, reporting an event that occurred on July 1, 2017. The filing pertains to corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and contains no financial data.
Material Changes
Effective July 1, 2017, the Company appointed Deanna Petersen as a new member of the Board of Directors. She will serve until the 2018 annual meeting of stockholders or until her successor is elected.
Management Commentary and Background
- Appointee Background: Ms. Petersen has served as Chief Business Officer of AVROBIO since January 2016. Previously, she was Vice President of Business Development at Shire Pharmaceuticals (2009-2015), where she led corporate strategy, partnering, licensing, and M&A activities.
- Rationale: The Board selected Ms. Petersen for her expertise in strategic planning and business development.
- Relationships: There are no family relationships between Ms. Petersen and existing officers/directors, and no reportable transactions exist between her and the Company.
Investor Verification Checklist
- Confirm the effective date of the board appointment (July 1, 2017).
- Verify Ms. Petersen's tenure at AVROBIO and Shire Pharmaceuticals.
- Check for any subsequent filings regarding her compensation or committee assignments.
- Note that this filing contains no financial results or guidance updates.